Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Kaempferol (KA) exists in a variety of herbal medicines. In vitro and in vivo studies have focused on the anti-Alzheimer effect of KA. However, little is known about its brain pharmacokinetic profile. The accumulated amount of KA in brain is very low because of the protection of blood-brain barrier (BBB). Borneol (BO) is a classical aromatic refreshing traditional Chinese medicine and commonly used as an adjuvant component of traditional Chinese medicines (e.g. compound Danshen dropping pills) in the treatment of cardiovascular and cerebrovascular diseases. According to the basic theories of traditional Chinese medicine, BO is called an "upper guiding drug", which can guide other components to the targeting tissues or organs in the upper part of the body, especially in the brain.MATERIALS AND METHODS: The probes for blood and brain sampling were implanted within the jugular vein/right atrium and right hippocampus of SD rats, respectively. Rats were intravenous administered of KA (25 mg/kg) alone or combined with BO (15, 30 mg/kg) via caudal vein. The blood and brain microdialysates were collected every 15 min for 180 min and every 30 min for 180-300 min. A selective and sensitive high performance liquid chromatography-chemiluminescence method was developed for the determination of unbound KA in rat blood and brain microdialysates, which can be converted to their actual free-form concentrations based on the in vivo relative recoveries of KA across microdialysis probes.RESULTS: KA quickly crossed the BBB to enter the extracellular fluid of hippocampus and reached the maximum concentration of 0.11 μg/mL within 30 min. The brain bioavailability and brain delivery of KA evidently increased with the co-administration of 15 and 30 mg/kg of BO. The AUC0-inf of KA in brain increased 1.84 and 2.19 times, and the Cmax of KA in brain increased 2.09 and 3.18 times than that without BO, respectively. In addition, the brain-to-blood distribution ratio of KA increased by 48.68% and 57.97% compared with that without BO. However, no significant difference in the T1/2 of unbound KA in blood aserved between three groups.CONCLUSIONS: BO can enhance the BBB permeability and improve the transportation of KA to brain. The dose-dependent effect of BO on the brain pharmacokinetic parameters of KA was observed. This co-administration strategy can be designed to enhance the brain accumulation of other neuropsychiatric medications.

Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies

Borneol promotes oral absorption and penetration into brain of puerarin and catalpol

Improvement in Solubility and Bioavailability of Puerarin by Mechanochemical Preparation

Oral Bioavailability and Lymphatic Transport of Pueraria Flavone-Loaded Self-Emulsifying Drug-Delivery Systems Containing Sodium Taurocholate in Rats.

[Borneol promotes catalpol and puerarin crossing through blood-brain barrier in focal cerebral ischemic rats].

The mechanism of the opening of the blood–brain barrier by borneol: A pharmacodynamics and pharmacokinetics combination study

Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

The effects of borneol on the pharmacokinetics and brain distribution of tanshinone IIA, salvianolic acid B and ginsenoside Rg1 in Fufang Danshen preparation in rats

Effect of borneol on the distribution of gastrodin to the brain in mice via oral administration

Oral Delivery of Puerarin Nanocrystals to Improve Brain Accumulation and Anti-Parkinsonian Efficacy.

Borneol for Regulating the Permeability of the Blood-Brain Barrier in Experimental Ischemic Stroke: Preclinical Evidence and Possible Mechanism

Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo.

Improved blood–brain barrier distribution: Effect of borneol on the brain pharmacokinetics of kaempferol in rats by in vivo microdialysis sampling

Effects of Different Preparation Technologies on Concentrations of Puerarin and Catalpol in Plasma and Brain of Rats after Oral Administration

Borneol-Modified Schisandrin B Micelles Cross the Blood–Brain Barrier To Treat Alzheimer’s Disease in Aged Mice

Effects of Borneol on the Release of Compound Danshen Colon-Specific Osmotic Pump Capsule In Vitro and Pharmacokinetics Study in Beagle Dogs

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson's Disease

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Research on the synergy of different doses of borneol and Chuanxiong Rhizoma on the anti-ischemnia effect in different brain regions

Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles